Breast cancer is the most common cancer in women, with a lifetime risk of around 1 in 8. While the median age of diagnosis is 61, 5% of cases are diagnosed in women in their 30s. Understanding the basic breast anatomy, imaging studies like mammograms, and pathology reports which detail cancer stage and biology is important for deciding on treatment. Stage is based on tumor size and lymph node involvement. Higher grade or larger tumors have a greater chance of lymph node spread. Genetic testing can help determine prognosis and optimal treatment for early-stage cancers.
Early Stage Breast Cancer and Radiation TherapyMatthew Katz
These slides are intended as an educational overview for newly diagnosed early stage breast cancer patients. My hope is that it can complement and enhance the doctor-patient relationship and shared decision making. I welcome any feedback on how to improve it.
Early Stage Breast Cancer and Radiation TherapyMatthew Katz
These slides are intended as an educational overview for newly diagnosed early stage breast cancer patients. My hope is that it can complement and enhance the doctor-patient relationship and shared decision making. I welcome any feedback on how to improve it.
Join Dr. Erica Mayer, medical oncologist at Dana-Farber/Brigham and Women's Cancer Center, to learn about exciting metastatic breast cancer developments from the past year. Dr. Mayer presents an overview on metastatic breast cancer and the subgroups, including Hormone Receptive, HER2+, and Triple Negative, and highlights recent advances for each of these subgroups. She also discusses the importance of clinical trials and what it means to participate in a clinical trial.
For more information on the Breast Cancer Treatment Center at Dana-Farber Cancer Institute, please visit:
http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
Join Dr. Erica Mayer, medical oncologist at Dana-Farber/Brigham and Women's Cancer Center, to learn about exciting metastatic breast cancer developments from the past year. Dr. Mayer presents an overview on metastatic breast cancer and the subgroups, including Hormone Receptive, HER2+, and Triple Negative, and highlights recent advances for each of these subgroups. She also discusses the importance of clinical trials and what it means to participate in a clinical trial.
For more information on the Breast Cancer Treatment Center at Dana-Farber Cancer Institute, please visit:
http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx
What are the latest treatment advances for HER2-positive metastatic breast cancer? Eric Winer, MD, director of the Breast Cancer Program in the Susan F. Smith Center for Women's Cancers, discusses some of the latest research and treatment options.
This presentation was originally given as part of the 2015 Metastatic Breast Cancer Forum, held on October 17 at Dana-Farber Cancer Institute in Boston, Mass.
For more information, visit www.susanfsmith.org
A detailed ppt about cancer immunotherapy.
includes:-
Immunosurveillance and Immunoediting
Dentritic cell vaccines
Antibody therapy
Combined therapy
immune blockades
Cytokine therapy
T cell therapy
Include latest research finding about therapy.
Timberland Medical Centre is a private hospital that has been in operation since 1994. We are strategically located at the 3rd Mile roundabout on Jalan Rock, Kuching, Sarawak, East Malaysia. Our hospital is 10 minutes from the Kuching International Airport and 15 minutes from the Central Bus Terminal. We continually seek to improve and upgrade our services and facilities, as we strive to provide the best medical care for our patients and customers.
This presentation is by Dr. Wong Kwong Hieng (General Surgeon at Timberland Medical Clinic) and covers what is breast cancer, and the breast cancer treatment available in Kuching, Sarawak, East Malaysia.
For more information, visit https://www.timberlandmedical.com
breast cancer is a disease which is more common in females. Introduction and definition of breast cancer is explained in slides. Incidence according to american cancer society estimation in united states 2023 is explained here.Types of breast cancer elaborated through images . Stages, pathophysiology, sign and symptoms, essential diagnostic evaluation of breast cancer and TNM classification in detail
described. Medical management includes chemotherapy, neoadjuvant therapy, adjuvant therapy, endocrine therapy, various radiation therapy etc. Pharmacological management described. Surgeries of breast cancer described. Nursing management and post operative management explained .Nursing diagnosis of breast cancer is prioritized.
How useful are advance directives in directing end of life care and do people really understand or want to know the true status of their health as the end nears?
Understanding how intermittent fasting may not only help weight loss but have multiple other health benefits including life prolongation, preventing cancer and dementia
2. • Breast cancer most common cancer in women (29% cases)
• Life time risk of 12.38% (one in eight)
• Median age at diagnosis is 61 but (5% 30s, 18% in 40’s, 25%
50’s)
Age Distribution 5 Year Survival by Stage
3. What You Need to Understand About Breast
Cancer Before Deciding on Treatment
4. What You Need to Know About Breast Cancer Before
Deciding on Treatment
• Understand the basic anatomy (lobules, ducts and lymph nodes)
• Breast imaging studies (mammograms or ultrasound) CT, MRI, PET
• Stage (particularly lymph node status)
• Biopsy or pathology report tell you about the biology (how aggressive) of
the cancer
1. Pectoralis Muscle, 2. Fatty Breast Tissue, 3.
Breast Cancer, 4. Breast Glands (lobules), 5.
Milk Ducts
5.
6. Lymph Nodes
supraclavicular
Internal mammary
axillary
The tail of the
breast may extend
high into the
axilla
8. Imaging
a case of advanced
cancer… 3 views of the
same tumor in a woman
with a 2.7 cm breast
cancer
Most women are
diagnosed at an early
stage with abnormal
calicifications on their
mammogram
9. Mammograms may often show areas of
calcification, which can be benign or
malignant
10. Mammograms may often show areas of
calcification, these may be malignant. In ductal
carcinoma in situ (DCIS), there is normally no mass
but just an area of calcification
17. Breast MRI
Will show the breast tumor
as well as the lymph nodes
Mastectomy = 6cm lobular cancer with 41 out
of 42 lymph nodes positive for cancer spread
28. Stage is based on the tumor size
(T1 – T4)
T 0 = DCIS
T1 = 2cm
T2 = > 2 – 5cm
T3 = > 5cm
29. Stage is based on lymph node spread
(N1 – N3)
N0 = no nodes
N1 = 1 -3 nodes
N2 = 4 – 9 nodes
N3 = 10 nodes
or SCV or IMC
30. Odds of Spread to Sentinel Node
The bigger the
tumor the more
likely it has spread
to the lymph nodes
Tumor size in cm
If the biopsy shows
a more aggressive
form of cancer (high
grade cancer) or
cancers cells are
seen in vessels (LV)
then there is a high
chance the cancer
has spread to the
nodes
Grade and LV invasion
32. So the stage if based on both the tumor size or the lymph
node status, so stage IIB would be T2N1 or T3N0
N0
T3
N1 T2
33. Mortality based on size of cancer and number
of lymph nodes involved
6 + Nodes
3 + Nodes
0 + Nodes
Tumor size in cm
34. Mortality based on cancer grade for node
negative and node positive cancers
2cm tumor
with 3 + nodes
2cm tumor
with 0 + nodes
Cancer Grade
35. Understanding a Pathology
Report
1. Invasive or Not (DCIS, LCIS)
2. Histology: what type of cancer
3. Grade: fast or slow growing
4. Hormone Receptors: is it sensitive to estrogen or progesterone
5. HER2 (human epidermal growth factor receptor 2) a genetic
mutation
40. Types of Invasive Breast Cancer
Histology Common Aggressive
Invasive Ductal 50 – 75% Average
Invasive Lobular 10 – 15% Average
Medullary 1 – 5% More
Mucinous (colloid) 1 – 5% Less
Papillary (<1%) Less
Tubular (1 – 5% Less
41.
42. Cancer Cell
A genetically altered or mutated
normal cell that results in
uncontrolled growth and spread
If the cell has not mutated too much it almost looks like a normal cell
(and would be called low grade or well differentiated) would
probably still have a normal response to estrogen and be less
aggressive (less likely to spread or grow rapidly)
43. Breast Cancer Grade
Grade Description 5Y Survival
1 (low) Well-differentiated, slow growing 95%
2 (most common) Moderately formed 75%
3 (high) Poorly formed, aggressive 50%
44. Hormone Receptors
Normal breast cells are sensitive to hormones (estrogen and progesterone)
and have chemical receptors that the hormones attach to. About 60 to
70 % of breast cancer cells with still have these receptors.
This is good for two reasons:
1. The cancer cells are less mutated (or dangerous) and the patient's
prognosis (outlook) is better
2. Instead of just chemotherapy the woman may benefit from a hormone
blocking drug like Tamoxifen (if she’s premenopausal) or an aromatase
inhibitor like Femara, Aromasin or Arimidex
45. HER2
(Human Epidermal Growth Factor Receptor Type 2)
About 20 to 30% of the cancers will have the genetic mutation that leads to
abnormal function of the HER2 gene. This is considered a more serious type of
cancer but there are antidote drugs available like Herceptin (trastuzamab) against
these cells
47. Gene expression array methodology
A) RNA from a tumor probes for thousands of genes have been affixed. B) The red
(relative overexpression in tumor) and green (relative underexpression in tumor)
intensities can be analyzed simultaneously. C) Depending on the supervision of the
analysis, tumors can be subtyped (as shown here), or can be analyzed for gene sets
associated with clinical outcome.
48. Genetic Profiles
May show that some women with favorable breast cancer (estrogen + and
node -) may need more than just Tamoxifen / analyze the cancer for the
presence (expression of 21 breast cancer genes)
49. Genetic Profiles
May show that some women with
favorable breast cancer (estrogen
+ and node -) may need more
than just Tamoxifen
27% of women had
a high risk gene
profile and 30.5%
relapsed after
Tamoxifen and they
may have done
better with
chemotherapy
50. MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-
gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage
breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen
Receptor status and any prior treatment.
Unlike previous generation genomic tests, MammaPrint interrogates all of the critical molecular
pathways involved in the breast cancer metastatic cascade. It analyzes 70 critical genes that comprise a
definitive gene expression signature and stratifies patients into two distinct groups — low risk or high
risk of distant recurrence. With MammaPrint, there are no intermediate results.
Hormonal therapy alone (e.g. Tamoxifen) may be sufficient to further reduce her risk if your patient is
Low Risk by MammaPrint, when combined with traditional risk factors. Conversely, if she is High Risk
by MammaPrint and has additional risk variables, more aggressive therapy including chemotherapy may
be recommended.